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In this study, we investigated the humoral immune response (through the release of
IgG, IgA, and IgM antiphage antibodies) to a staphylococcal phage cocktail in patients
undergoing experimental phage therapy at the Phage Therapy Unit, Medical Center of
the Ludwik Hirszfeld Institute of Immunology and Experimental Therapy in Wrocław,
Poland. We also evaluated whether occurring antiphage antibodies had neutralizing
properties toward applied phages (K rate). Among 20 examined patients receiving the
MS-1 phage cocktail orally and/or locally, the majority did not show a noticeably higher
level of antiphage antibodies in their sera during phage administration. Even in those
individual cases with an increased immune response, mostly by induction of IgG and
IgM, the presence of antiphage antibodies did not translate into unsatisfactory clinical
results of phage therapy. On the other hand, a negative outcome of the treatment
occurred in some patients who showed relatively weak production of antiphage
antibodies before and during treatment. This may imply that possible induction of
antiphage antibodies is not an obstacle to the implementation of phage therapy and
support our assumption that the outcome of the phage treatment does not primarily
depend on the appearance of antiphage antibodies in sera of patients during therapy.
These conclusions are in line with our previous findings. The confirmation of this thesis
is of great interest as regards the efficacy of phage therapy in humans.
Keywords: antibodies, antimicrobials, ELISA, immune response, phage cocktail, phage therapy, Staphylococcal
Infections
INTRODUCTION
Phage treatment is considered one of the most promising therapies in fighting human pathogenic
bacterial strains, including those that are antibiotic resistant such as methicillin-resistant
Staphylococcus aureus (MRSA). Due to constantly declining effectiveness of antibiotics, pathogenic
bacteria have become endemic organisms, especially in medical care units (Arnold et al., 2011;
Cheon et al., 2016). Regardless of such worldwide increasing microbiological hazard, the wider
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use of phages faces skepticism over its effectiveness, as it was
postulated that human antibodies may have a negative effect on
favorable treatment results (Sulakvelidze et al., 2001). Herein, we
estimate the induction of antiphage antibodies and their potential
neutralizing influence on S. aureus MS-1 phage cocktail.
Data regarding the antiphage humoral response during phage
treatment are still extremely scarce. Only a few articles describe
antibacteriophage activity of human sera of patients during phage
treatment and healthy volunteers (Kucharewicz-Krukowska and
S´lopek, 1987; Bruttin and Brussow, 2005; Górski et al., 2007;
Łusiak-Szelachowska et al., 2014). Kucharewicz-Krukowska and
S´lopek (1987) reported that induction of antiphage antibodies
was detected in 54.4% of patients during therapy (the 10th day
of phage treatment, oral administration). Only in 3 of 57 patients
(5.3%) did sera indicate high antiphage activity. Similarly, in
the experiment by Bruttin and Brussow (2005), none of the
examined volunteers showed an increased level of antiphage
antibodies (IgG, IgA, and IgM) after oral administration. Among
122 patients from the Phage Therapy Unit in Wrocław, only 15
of them (12.3%) demonstrated high (K > 18) antiphage activity
of sera (AAS), mostly during local administration (Łusiak-
Szelachowska et al., 2014). The same report showed no clear
correlation between phage administration and increased level of
antiphage antibodies in patients’ sera evaluated by absorbance
measurements using the ELISA test. Further studies (Łusiak-
Szelachowska et al., 2016) clearly showed that AAS depends
on the route of phage administration. All patients receiving
staphylococcal phage preparations orally showed a low level of
AAS, whilst those with local administration of phage cocktail
had high AAS in almost half of the cases. Generally, use of
a phage cocktail resulted in a stronger immune response than
monotherapy. With regard to the relatively small number of
patients with such high activity of sera, it is difficult to define
the relationship between serum antiphage activity, the level of
antiphage antibodies and effectiveness of the phage therapy. It
has to be said that induction of antiphage antibodies and their
binding to phage antigens does not necessarily mean the loss of
phage viability (Górski et al., 2012).
Our group (Łusiak-Szelachowska et al., 2014) published
probably the first report where the production of antiphage
antibodies was compared to their neutralizing properties and
was related to the clinical outcome in patients receiving phage
therapy. The results shown below are a continuation of the
previous research. Both papers allow one to determine whether
phage therapy induces production of neutralizing antiphage
antibodies and whether they are associated with the results of the
treatment.
MATERIALS AND METHODS
Ethics Approval Statement
Experimental phage therapy was approved by the Bioethics
Committee at the Wrocław Medical University (approval number
KB-349/2005 with further amendments) and was conducted in
accordance with the Declaration of Helsinki and national rules
governing experimental therapy. Each patient gave informed
consent prior to beginning the treatment. The study was
approved by the same bioethical commission (approval number
KB-414/2014).
Patients Subjected to Phage Therapy
and Healthy Volunteers
Adult patients with various infections (e.g., bone infections,
sinus infections) resistant to antibiotic treatment received phage
treatment under the therapeutic protocol entitled “Experimental
phage therapy of drug-resistant bacterial infections, including
MRSA infections” (Mie˛dzybrodzki et al., 2012). Patients (n= 20)
treated in the Phage Therapy Unit in Wrocław, Poland with
the S. aureus MS-1 phage cocktail were examined. Nineteen of
them suffered from infections caused by methicillin-sensitive
Staphylococcus aureus strains (MSSA); from one patient the
Staphylococcus lugdunensis strain was isolated. All patients
received treatment over the years 2012−2015. Specific data
regarding patients examined in this study are summarized in
Table 1. Sera of 10 healthy blood donors came from the Blood
Donation Center, Clinical Military Hospital in Wrocław, Poland.
The effectiveness of phage treatment was evaluated according
to the scale from A to G (Mie˛dzybrodzki et al., 2012) where
categories A-C were considered as good responses to the phage
therapy (A – pathogen eradication, B – good clinical results,
C – clinical improvement) and categories D-G were considered
as inadequate responses to phage treatment (D – questionable
clinical improvement, E – transient clinical improvement, F – no
response to the treatment, G – clinical deterioration).
The details of patient treatment including routes of
administration in different types of infections have been
described earlier (Mie˛dzybrodzki et al., 2012).
Phage Preparations
Testing Bacterial Susceptibility to Phages
The MS-1 phage cocktail consists of three lytic S. aureus
phages – 676/Z, A5/80 and P4/6409. Among 458 tested MSSA
strains of S. aureus, 73.4% were susceptible to the MS-1 phage
cocktail. Effectiveness was lower for MRSA strains (from 28
tested strains 53.6% of them were susceptible to MS-1 phage
cocktail). Detailed analysis of susceptibility to the MS-1 phage
cocktail is presented in Table 2. The phage components of
MS-1 cocktail were chosen to achieve optimal (maximal) lytic
range based on the theoretical statistical analysis of the results
of the sensitivity of staphylococcal strains against individual
staphylococcal phages from our collection. The results shown in
Table 2 are presented for new collection of staphylococcal strains
isolated from patients after introduction of MS-1 phage cocktail.
Therefore, they represent a real staphylococcal sensitivity to MS-1
as well as to its individual phages. We are working on new, more
efficient composition of staphylococcal phage cocktail based on
the results and experience obtained from using MS-1. All our
patients are treated with targeted phage preparations, which
means that in each case we use only phages or phage cocktail
which are lytic against a pathogenic bacterial strain isolated from
the patient. Therefore, in all our MRSA cases treated with MS-1,
the bacteria were susceptible to the phage cocktail. Otherwise, our
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TABLE 1 | List of examined patients from the Phage Therapy Unit in Wrocław, Poland.
Patient Type of infection Preparation used in phage therapy Route of administration
1 Left shank infection OP MS-1 Locally
2 Right hip joint fistula MS-1 Locally
3 Chronic infection of the paranasal sinuses and
the maxillary sinus
MS-1 Locally and orally
4 Ulceration of perianal area after colon resection MS-1, since 77th day of therapy S. aureus A5/80
phage, after 5-month interruption S. aureus ϕ200
phage
All phages were applied locally and
orally
5 Inflammation of the left tibia MS-1 First locally, after 8 weeks of the
treatment orally
6 Infection of the subcutaneous tissue with a
thigh fistula
MS-1, since 105th day of therapy S. aureus 676/F
phage
all phages were applied orally
7 Left elbow infection with active fistula MS-1 Locally
8 Periprosthetic infection of the left hip OP MS-1 TOP, since 42nd day of therapy S. aureus
ϕ200 phage
OP MS-1 TOP phage cocktail was
applied locally, ϕ200 phage orally
9 Inflammation of the left tibia MS-1 Locally
10 Fracture of the ankle with ulceration MS-1, after 8-month interruption S. aureus 676/F
phage
Locally, after 8.5 months of the
treatment orally, 676/F phage was
applied only orally
11 Chronic infection of the paranasal sinuses and
the throat
MS-1 locally and orally
12 Inflammation of the right calcaneus MS-1 Locally
13 Right foot infection MS-1 Locally
14 Chronic infection of the paranasal sinuses MS-1, since 35th day of therapy S. aureus P4 phage Orally, P4 phage was applied locally
and orally
15 Chronic conjunctivitis, chronic sinusitis MS-1, after two months treatment S. aureus A3/R
phage
all phages were applied Locally and
orally
16 Periprosthetic infection of the right hip MS-1 Locally
17 Inflammation of the right femur MS-1 Locally
18 Surgical wound infection of the belly with fistula MS-1 Orally
19 Right thigh infection MS-1 Locally
20 Chronic purulent inflammation of the right tibia MS-1 Locally
TABLE 2 | Susceptibility of S. aureus MSSA and MRSA strains to MS-1 phage cocktail (Weber-Da˛browska et al., 2012; unpublished data).
MS-1 676/Z A5/80 P4/6409
Susceptible (MSSA) 336 (73.4%) 260 (72.8%) 252 (70.6%) 192 (53.8%)
Resistant (MSSA) 122 (26.6%) 97 (27.2%) 105 (29,4%) 165 (46.2%)
TOTAL 458 (100%) 357 (100%) 357 (100%) 357 (100%)
Susceptible (MRSA) 15 (53,6%) 4 (57.1%) 3 (42.9%) 2 (28.6%)
Resistant (MRSA) 13 (46,4%) 3 (42.9%) 4 (57.1%) 5 (71.4%)
TOTAL 28 (100%) 7 (100%) 7 (100%) 7 (100%)
MRSA patients were treated with another single staphylococcal
phage from our collection. If we were not able to identify an
active phage, patients were not qualified to experimental phage
treatment.
Bacterial susceptibility to specific polyvalent staphylococcal
phages from our collection was evaluated by spotting method
(S´lopek et al., 1983; Chirakadze et al., 2009). The bacteria cultures
were prepared in liquid broth medium. Next, the suspensions
were spread on plates with solid agar medium. Plates were dried
in incubator (37◦C, 1.5 h). Drop of each phage lysate (107−109
pfu/ml of initial suspension) was spotted on plate surface, then
plates were incubated (37◦C, 6 h) and stored at 4◦C until
the following day. A positive result was recognized (under the
therapeutic point of view) when confluent or semi-confluent lysis
was observed.
Phage Propagation
All phages used in this study were propagated in liquid broth
(LB). To each of five flasks, containing 160 ml of medium, 5 ml
overnight host bacterial culture was added, mixed together and
incubated for 1 h at 37◦C. At the same time one large flask (3−5 l
capacity) was filled with a mixture of LB (160 ml), 5 ml of high
titre phage stock (at least 108−109 pfu/ml) and 5 ml of overnight
host strain culture. After an 1 h incubation period the content
of one of the five flasks was added to a large flask. This step
was repeated every 30 min until the last flask was emptied. From
Frontiers in Microbiology | www.frontiersin.org 3 October 2016 | Volume 7 | Article 1681
fmicb-07-01681 October 20, 2016 Time: 17:44 # 4
Z˙aczek et al. Antibody Production against Staphylococcal Phages
the moment of the phage addition the culture was incubated for
10 h at 37◦C. After this step the large flask was stored under
refrigeration at 4◦C. The following day, phage culture was filtered
aseptically using membrane filters (0.22 µm) in a laminar flow
cabinet and its titer was determined.
Therapeutic Phage Preparations
All examined patients (with two exceptions) received phage
cocktail lysates (MS-1) produced by IBSS BIOMED S.A. in
Kraków, Poland. According to the leaflet, the therapeutic phage
dose was at least 5 × 105 pfu/ml. One patient received a
purified phage cocktail (OP MS-1) with a phage dose of at least
1 × 109 pfu/ml of each phage suspended in phosphate buffered
saline (PBS) with 10% addition of saccharose. Finally, one
patient received an analogous purified phage cocktail deprived of
saccharose (OP MS-1 TOP). Saccharose is used to maintain the
stability of storage conditions, including structure preservation
and specific interactions (Chang et al., 2005). Typically, phages
were applied orally and/or locally 2−3 times a day in the amount
of 5−10 ml per dose (each case was individually evaluated
by a physician). Before each oral phage administration 10 ml
of oral suspension of dihydroxyaluminium sodium carbonate
(68 mg/ml) was applied as well.
Purified Phage Preparations
Due to high sensitivity of the ELISA technique, all phage
preparations used in our examinations (676/Z, A5/80, and
P4/6409) were purified according to a previously described
method (Łusiak-Szelachowska et al., 2014) with some changes.
After phage propagation in LB liquid medium, phage lysates were
concentrated using Vivaflow 200 (tangential flow module) with
Hydrosart membrane (the molecular weight cut-off is 30 000).
The next step was removal of lysate contaminants from the phage
suspension by size exclusion chromatography using a Sepharose
CL-4B column (GE Life Sciences 26/100) under the following
conditions: elution buffer 0.068 M phosphate buffer, pH 7.2;
flow rate 2.2 ml/min; detection UV at 280 nm. Sepharose CL-
4B is a cross-linked form of Sepharose, which is chemically
and physically more resistant than Sepharose itself and offers
better flow characteristics with the same selectivity. Purified
phage particles were dialysed to PBS. The final titers ranged
from 1.3 × 1010 to 3.5 × 1010 pfu/ml. To evaluate the level
of endotoxins, the Endpoint Chromogenic Limulus Amebocyte
Lysate (LAL) test was performed, according to the manufacturer’s
instructions (Lonza). The LAL test is a quantitative test mainly
for Gram-negative bacterial endotoxins. However, it is helpful
to detect endotoxins in every phage preparation. As our findigs
revealed, LPS can be present even in sterile peptone water. It
happens because we use reusable glass tubes and LPS is well
known for its very strong adhesion properties. Even relatively
low dose of LPS at the beginning of phage propagation and
purification is multiplied during the concentration process. The
final levels of detected endotoxins in phage preparations varied
from 994 to 1727 EU/ml, which gave no more than 20 EU/ml after
dilution of phage preparations for ELISA purposes. Similar low
values were detected in staphylococcal phage preparations used
in phage therapy.
Preparation of Serum Samples
All blood samples were taken before and during treatment, in
some cases also after phage therapy. The sera were separated from
heparinized blood samples by centrifugation at 1,500 g for 10 min
and stored in 1−1.5 ml aliquots in a freezer at−70◦C.
Phage Inactivation
The phage neutralization by human sera was estimated as the rate
of phage inactivation (K rate) by the method described in our
previous work (Łusiak-Szelachowska et al., 2014). Fifty microliter
of phage lysate (1 × 106 pfu/ml) was added to 450 µl of diluted
serum (from 1:10 up to 1:1500). Next, sample was incubated at
37◦C for 30 min. After incubation the mixture was diluted 100
times with cold broth and the phage titer was determined. K rate
was estimated using the equation:
K = 2.3 × (D/T) × log(P0/Pt) (1)
where, K is the rate of phage inactivation, D is the reciprocal of the
serum dilution, T stands for the time in minutes during which the
reaction occurred (30 min. in this case), P0 is the phage titer at the
start of reaction and Pt is the phage titer after reaction. A K rate
less than 5 was considered as weak phage neutralization, between
5 and 18 as a medium level, and above 18 as a high level of phage
neutralization.
ELISA Procedure
Immune analysis was based on detection of the level of specific
antiphage antibodies in human sera reacting with phage antigens
using an indirect ELISA technique. We used three different types
of secondary antibody to detect specifically human IgG, IgA,
and IgM. In contrary to our previous results based only on raw
absorbance values (Łusiak-Szelachowska et al., 2014), herein we
established standard reference serum and final results have been
provided as antibody units (AU). The immunological response
was measured to each phage separately (S. aureus 676/Z, A5/80,
and P4/6409 phages) as well as to the entire S. aureus MS-1
phage cocktail. Purified S. aureus phage preparations as antigens
were diluted immediately before use in 0.05 M coating buffer
(carbonate−bicarbonate buffer; Sigma−Aldrich) to obtain the
titer at 5 × 108 pfu/ml. The phage cocktail was prepared after
diluting phages in coating buffer by mixing equal volumes of
three different S. aureus phage solutions (676/Z, A5/80, and
P4/6409).
At the beginning of the procedure, 96-well flat-bottom
microplates (Nunc MaxiSorp; Thermo Scientific) were loaded
with 100 µl of purified phage preparations as antigen-containing
samples. Next, covered microplates were incubated for 1 h at
37◦C and washed six times using PBS with 0.05% addition
of Tween 20 (Sigma−Aldrich), which is a synthetic detergent
helpful in removing non-binding residue antigens. Multiple
washing was a mandatory stage in the procedure after each
incubation period at 37◦C. The washing step was performed by
an automatic 96-needle microplate washer (HydroSpeed; Tecan)
with a wash rate at 350 µl/s. The next step was to apply to
microplate wells 200 µl of blocking protein (1% solution of
casein sodium salt from bovine milk in PBS; Sigma-Aldrich) for
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blocking any non-specific binding sites. Microplates were then
again incubated for 1 h at 37◦C. As primary antibodies human
serum samples, diluted in blocking solution with 0.05% addition
of Tween 20 in the proportions 1:1000 and 1:10 000, were used.
Each serum sample was applied in duplicate by pipetting 100 µl
of the solution per well. After that, microplates were incubated
for 1 h at 37◦C. Specific antiphage antibodies bound with antigen
were detected by secondary antibodies. We used three different
secondary antibodies produced in goat linked with the enzyme
horseradish peroxidase (HRP) binding human IgG, IgA or IgM
(Sigma−Aldrich). All anti-human secondary antibodies were
diluted in blocking solution with 0.05% addition of Tween 20
in the proportion 1:15 000 to obtain working concentrations
at ∼0.5 µg/ml. Microplates were loaded with 100 µl/well of
secondary antibody solution and again incubated for 1 h at 37◦C.
The final step was to apply 200 µl/well of a chemical substrate
(o-Phenylenediamine; Sigma−Aldrich) suspended in 0.05 M
phosphate-citrate buffer containing 0.03% sodium perborate
(Sigma−Aldrich) that is converted by the enzyme into a color
measured spectrophotometrically to determine the presence and
quantity of antiphage antibodies. Microplates with a substrate
were incubated at room temperature for 30 min in the dark. After
the incubation period, microplates were read on a multiwell plate
reader (Sunrise; Tecan) using Magellan 7.1 software at 450 nm
with shaking immediately before the reading. One series of the
whole procedure closed at 1 day. We avoided night storage of
loaded microplates in refrigerated conditions as low temperatures
had an influence on the repeatability of the results. The value of
absorbance in blank wells (filled only with buffer) was subtracted
from the tested samples.
To verify the reliability of the tests, a series of control samples
was carried out on each microplate to detect possible errors. To
evaluate the blocking properties of casein solution as well as to
detect any non-specific binding of human antiphage antibodies
(IgG, IgA, IgM) on microplate surface some wells were loaded
with coating buffer (without phages as antigens). To detect
unusual cross-reactivity between the antigen and the secondary
antibody, some microplate wells contained a control human
serum sample deficient in IgG, IgA and IgM (Sigma−Aldrich).
Control serum was prepared according to the manufacturer’s
instructions in the same solution as all human serum samples.
Some wells were loaded only with secondary antibody and
substrate to detect any unusual endogenous reaction product.
Of note, none of the above-mentioned control samples ever
gave higher values of absorbance than blank wells. This means
excellent selection of procedure parameters and reagents (data
not shown). No cross-reactivity was observed with any of the
potential cross-reactants tested.
Establishing a reference standard serum encountered some
difficulties. Contrary to previous studies (Miura et al., 2008;
Da˛browska et al., 2014) we worked only on a human model. We
could not immunize healthy humans with phages for obvious
reasons. No commercial kit for detection of the human antiphage
antibodies is yet available on the market as well. Obtaining a
sufficient amount of highly reactive patient’s serum was limited
due to a small volume of blood samples taken from patients
and a relatively weak signal obtained in the ELISA test. From
several dozen samples we chose two representatives; one was
used for assessing IgG and IgM antibody levels, and the second
one was used for assessing IgA levels. Dilutions of standard
sera were made in twofold steps starting with 1:100 for IgA
and IgM and 1:1000 for IgG to generate a four-point standard
curve for each type of antibody. The AU were then calculated
from their absorbance values at 450 nm using the parameters
estimated from each standard curve (Miura et al., 2008). The
average value of each duplicate (per sample) was calculated. The
dilution giving an optical density at 450 nm of ≤1 was assigned
as 1 000 AU (AUs). Achieving high values of absorbance (∼1 at
450 nm) for IgG caused no problems for us. However, due to weak
reactivity of serum samples, we were able to obtain maximum
values of absorbance at 0.6 for IgM and 0.25 for IgA, respectively.
Reference sera as standards were run on each tested microplate.
Statistical Evaluation of the Data
The evaluation of statistical significance of differences between
groups in the neutralization test was performed using Wilcoxon’s
test (for dependent variables) and the Mann–Whitney U test (for
independent variables).
Results carried out by ELISA technique were analyzed using
Wilcoxon’s test (for dependent variables). For independent
variables, we used the Mann–Whitney’s U test and Student’s
t-test. To choose the appropriate statistical test we confirmed
whether in groups of IgG, IgA, and IgM antibodies distributions
were normal and whether there were homogeneous variances.
In case of normal distribution and homogeneous variances we
applied parametric Student’s t-test. In remaining cases we used
nonparametric Mann−Whitney’s U test.
Significance was set at p < 0.05 and p < 0.001. Analysis was
performed using the Statistica 10 software package.
RESULTS
As mentioned before, each patient subjected to experimental
phage therapy was treated individually by a physician in charge
according to the protocol of the experimental phage therapy
employed at the Phage Therapy Unit. Depending on the
overall health, the type of infection and its severity, a specific
treatment was applied after determination of the sensitivity
of isolated bacterial strains to the specific phage. Follow-up
visits (during which blood samples were taken) took place at
various time intervals in every single case. The number of
follow-up visits varied from 1 to 11 depending on the course
of the therapy. Sometimes the therapy was terminated by a
physician (if eradication of infection was achieved or poor
toleration occurred), while in other cases patients terminated
therapy themselves due to the lack of expected improvement
during treatment. Furthermore, the duration of the treatment
varied from one month to over a year (with interruptions).
The main criterion was patients’ clinical condition confirmed
by laboratory data. It should be emphasized that it is not
unusual for patients with chronic bacterial infections (in contrast
to acute infection episodes) to be treated with antibacterial
agents for months (Leekha et al., 2011). Thus, it is hard to
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summarize and standardize all collected data. Therefore, it
was impossible in this experimental therapy to standardize
sample collections similarly to protocols of clinical trials.
Here, we decided to focus on serum samples obtained before
therapy and on samples giving maximum levels of antiphage
antibodies during the whole treatment (in the case of a
single follow-up visit, we evaluated the one serum sample we
had). These results were compared with the level of phage
inactivation (K rate) measured in the neutralization test and
with the overall outcome of phage treatment for each patient
individually.
Effect of Phage Treatment on the Level
of Antiphage Antibodies
We focused mainly on the immune response to the S. aureus MS-
1 phage cocktail as phage preparations were applied exactly in
such composition to all patients. Here, we present the level of
anti-MS-1 phage IgG (AU) measured by the ELISA test for all
20 examined patients (Figure 1A). Values obtained individually
for all 10 healthy donors who had never been subjected to
phage therapy are shown in Figure 1B. The comparison of
these two groups (mean values) are presented in Figure 1C.
Due to the high diversity in the obtained results, the median
values for the group of patients during treatment were evaluated
(Figure 1A). The median level of IgG antibodies reached the
highest values in comparison to the levels of IgA and IgM
and was 78.95 AU. None of the healthy volunteers reached
this limit. The mean value of the level of antiphage antibodies
(IgG) for the group of patients before treatment was 61.71
AU and 166.62 AU during treatment. For healthy donors the
mean value was 27.75 AU. Earlier bacterial infections and
exposure to relevant phages were probably responsible for
higher initial antibody values in patients compared with healthy
individuals.
In contrast to the results described above, levels of
antiphage IgA were the lowest in the group of patients as
well as in the group of healthy donors (Figures 2A,B) in
comparison to the levels of IgG and IgM. In fact, we did not
detect any antiphage IgA in sera of healthy people. Similar
results were obtained in patients (60% of examined patients
FIGURE 1 | Levels of IgG anti-MS-1 phage antibodies in human sera. (A) Patients (n = 20) treated with S. aureus MS-1 phage cocktail. (B) Healthy (n = 10)
donors. (C) Average values for patients treated with S. aureus MS-1 phage cocktail and healthy donors. Average values are plotted with the standard error (SE)
indicated by the error bars. Median value for the group of patients during treatment is marked on each graph by a horizontal dotted line.
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FIGURE 2 | Levels of IgA anti-MS-1 phage antibodies in human sera. (A) Patients (n = 20) treated with S. aureus MS-1 phage cocktail. An asterisk next to the
number of a patient means undetectable levels of antibodies before and during treatment. (B) Average values for patients treated with S. aureus MS-1 phage
cocktail before and during treatment. Average values are plotted with the SE indicated by the error bars. The average value for 10 healthy donors was zero. Median
value for the group of patients during treatment was zero as well.
indicated undetectable levels of IgA before and during the
whole treatment). This phenomenon occurred even in patients
with sinus infections, where the mucosal immune system
was stimulated by local administration of phages. Possibly,
higher levels of IgA would be detected in saliva instead of
serum. The median value of IgA obtained for the group of
patients during treatment was zero as well. The mean value
of the level of antiphage antibodies (IgA) for the group of
patients before treatment was 0.2 AU and 2.66 AU during
treatment.
The levels of anti-MS-1 phage IgM were the most surprising,
as we observed an astonishingly high spread between the lowest
and highest values in some patients (Figure 3A). Samples of two
patients reached levels over 1 000 AU as a response to local
phage administration (patients 7 and 17). In another two cases
we did not detect any IgM elicited by phage before or during
phage therapy (patients 13 and 15). Despite high levels of IgM
in some cases, the median value in the group of patients during
treatment was only 4.99 AU. The group of healthy subjects was
characterized by relatively low levels of IgM antiphage antibodies,
which were close to zero (Figures 3B,C). The mean value of
the level of antiphage antibodies (IgM) for the group of patients
before treatment was 11.84 AU and 205.89 AU during treatment.
For healthy donors the mean value was 0.81 AU.
Three patients (patients 7, 8, and 16 in Figures 1–3) with
markedly higher levels of all antibody isotypes (IgG, IgA, IgM)
were treated by phages locally. However, in cases with low levels
of IgG and IgM antiphage antibodies and with undetectable levels
of IgA antiphage antibodies (numbers 13 and 19 in Figures 1–3)
phages were applied likewise locally. These results are consistent
with our earlier report, where no relationship between the route
of administration and ELISA results was observed (Łusiak-
Szelachowska et al., 2014). Statistical analysis of ELISA results in
patients and healthy donors are summarized in Tables 3 and 4.
A long-term study of the four patients with the largest
numbers of control visits showed meaningful differences in the
levels of particular types of antiphage antibodies (Figures 4A–
D). Apparently, IgA antibodies in sera were not involved in
the humoral immune response during treatment as even long-
term exposure (several months) to phage antigens did not
induce secretion of IgA. In the case of patient 4 (Figure 4A),
the S. aureus MS-1 phage cocktail was applied only for the
first 76 days of therapy (S. aureus A5/80 and S. aureus ϕ200
phages were applied afterward). However, even a change of
medication resulted in a noticeably stronger immune response
by IgG antibodies to the MS-1 phage cocktail over a year after
its administration. No changes in secretion of IgA antibodies
were observed. In accordance with expectations, a marked
increase of IgM was noted before the IgG boost directly after
initiation of the treatment and after change of the phage
preparation (from S. aureus MS-1 phage cocktail to S. aureus
A5/80 phage). Analogously, even more rapid growth of IgM
levels at the beginning of the treatment was noted in patient 8
(Figure 4C). Such dependence was not observed in another two
cases (Figures 4B,D). IgG antibodies were mostly responsible
for the humoral immune response in patients undergoing phage
treatment. They persisted in the blood for several months
during phage administration. All four patients analyzed in
Figure 4 received, at a certain stage of the treatment, another
staphylococcal phage (different from the MS-1 phage cocktail).
We did not evaluate the immune response to other phages used
in treatment due to a lack of purified specific phage preparation.
Immunogenicity Depending on the Type
of Phage
As stated above, beside investigations on the MS-1 phage cocktail,
we measured likewise the immunological response to each phage
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FIGURE 3 | The levels of IgM anti-MS-1 phage antibodies in human sera. (A) Patients (n = 20) treated with S. aureus MS-1 phage cocktail. (B) Healthy
(n = 10) donors. An asterisk next to the number of a healthy donor means an undetectable level of antiphage antibodies. (C) Average values for patients treated with
S. aureus MS-1 phage cocktail and healthy donors. Average values are plotted with the SE indicated by the error bars. Median value for the group of patients during
treatment is marked on each graph by a horizontal dotted line.
TABLE 3 | Statistical analysis of ELISA results in 20 patients (response to
MS-1 phage cocktail).
Type of
antibody
Mean level of
antiphage antibodies
(AU) before
therapy ± SE
Mean level of
antiphage antibodies
(AU) during
therapy ± SE
Statistical
significance
(p)
IgG 61.71 ± 8.19 166.62 ± 43.06 0.008∗
IgA 0.2 ± 0.14 2.66 ± 1.79 0.049∗
IgM 11.84 ± 9.8 205.89 ± 88.71 0.002∗
∗Wilcoxon’s test.
from the cocktail separately. We chose two patients with a similar
course of treatment. One of them showed a relatively high level of
antiphage antibodies (especially IgA and IgM), while the second
one revealed a much lower immune response. We noted that the
response rate may depend not only on the type of applied phage
but also on the type of antibody involved in binding to phage
antigen. For IgG antiphage antibodies the most immunogenic
(excluding the MS-1 phage cocktail) was S. aureus A5/80 phage,
while for IgA it was S. aureus 676/Z phage (even if considering
generally low values for IgA antiphage antibodies). We did
not observe such coincidence for IgM antiphage antibodies. In
patient with high levels of IgM antibodies the response to each
phage reached a value over 500 AU after 20 days of the treatment.
In the second case, practically no phage-induced production
of IgM antibodies was observed (Figures 5A,B). Based on
these results, we can assume that differences in the phages’
immunogenicity are related to the various structure of phage
proteins, which is consistent with previous reports describing
animal models (Capparelli et al., 2007; Da˛browska et al., 2014;
Majewska et al., 2015).
Correlation between the Levels of
Antiphage Antibodies and Antiphage
Activity of Human Sera
Stimulation of neutralizing antibodies has been one of the
arguments of opponents of phage therapy. We observed a
correlation between increased level of antiphage antibodies
Frontiers in Microbiology | www.frontiersin.org 8 October 2016 | Volume 7 | Article 1681
fmicb-07-01681 October 20, 2016 Time: 17:44 # 9
Z˙aczek et al. Antibody Production against Staphylococcal Phages
TABLE 4 | Statistical analysis of ELISA results in 20 patients compared to
10 healthy donors (response to MS-1 phage cocktail).
Type of
antibody
Mean level of
antiphage antibodies
(AU) in healthy
people ± SE
Mean level of
antiphage antibodies
(AU) in patients
during therapy ± SE
Statistical
significance
(p)
IgG 27.75 ± 7.86 166.62 ± 43.06 <0.001∧
IgA 0 2.66 ± 1.79 0.305#
IgM 0.81 ± 0.28 205.89 ± 88.71 0.067∧
∧Mann−Whitney’s U test; #Student’s t-test.
detected in the ELISA procedure and higher rate of phage
inactivation (K) mostly for IgG and IgM antibodies. No
correlation was observed for IgA antibodies. Determining
which type of antibody (IgG or IgM) is characterized by the
strongest neutralizing properties toward phages is difficult, as
the obtained results for IgG and IgM coincide with each other
in almost every case with K > 18. However, it should be
mentioned that even a very high rate of phage inactivation
(K > 18) does not necessarily mean an unfavorable outcome
of phage treatment. All changes in the levels of antiphage
antibodies (IgG, IgA, IgM) measured by the ELISA test in
patients before and during treatment were statistically significant
(Table 3) at p < 0.05. Changes in the rate of phage
inactivation (K) observed before and during phage therapy
were statistically significant as well (Table 5) at p < 0.001.
Results regarding mean K rate in healthy donors compared to
patients during treatment are presented in Table 6. Summary
data related to the levels of antiphage antibodies, rate of phage
inactivation and clinical results of phage therapy are presented in
Table 7.
Rates of Inflammatory Markers in
Patients Treated with Phages
We also analyzed our data in the context of the selected
inflammatory markers (data not shown) in patients before
and during treatment. The inflammatory markers in patients’
blood were assessed by commercial laboratory methods. Two
classical inflammatory markers, CRP (C-reactive protein) and
FIGURE 4 | Levels of anti-MS-1 phage antibodies (IgG, IgA, IgM) before and during phage therapy and antiphage activity of sera (AAS, K rate) in four
patients with the largest number of control visits. (A) Patient 4; ∗means 5-month break between successive cycles of phage treatment, (B) Patient 6,
(C) Patient 8, (D) Patient 10; ∗means 8-month break between successive cycles of phage treatment. x, K rate was not estimated.
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FIGURE 5 | Immunogenicity depending on the type of phage in patients treated with S. aureus MS-1 phage cocktail. (A) Patient 7. (B) Patient 20. The
immunological response to each phage from the MS-1 phage cocktail was examined in the same way as phage cocktail. Purified single S. aureus phage
preparations as antigens were diluted immediately before use to obtain the titer at 5 × 108 pfu/ml. The phage cocktail was prepared after diluting single phages in
coating buffer by mixing equal volumes of three different S. aureus phage solutions (676/Z, A5/80, and P4/6409).
ESR (erythrocyte sedimentation rate) were considered. They
are believed to be the most valuable markers for evaluating a
patient’s clinical status with respect to inflammation, infection,
trauma or malignant disease (Saadeh, 1998; Mie˛dzybrodzki et al.,
2009; Assasi et al., 2015). In the majority of cases both markers
remained constant (with slight variations within the values) or
were even lower during treatment than before phage therapy. In
some cases, both markers decreased despite constantly increasing
levels of antibodies (IgG and IgM) during treatment. Such data
are partially consistent with previous results. Mie˛dzybrodzki
et al. (2009) indicated a statistically significant reduction in
mean CRP concentrations in patients during the first five weeks
of phage treatment. Jon´czyk-Matysiak et al. (2015) observed
that phage therapy had no effect on the level of inflammatory
markers, ESR and CRP, when all data from patients observation
were analyzed. Data are only partially consistent because the
different patient cohorts, with various infections and undergoing
different course of the treatment have been evaluated. It should
be pointed out that purified phage preparations were applied
in two cases (patient 1 was taking OP MS-1, whereas patient 8
was taking the OP MS-1 TOP phage preparation). Surprisingly,
these two patients receiving purified phage preparations showed
increased values of CRP during treatment (from 5.71 before
therapy to 17.39 mg/l after two months of continuous treatment
in patient 1 and from 5.9 to 8.52 mg/l after five weeks
of treatment in patient 8). Furthermore, the purified phage
preparations had no effect on lower induction of antibodies at
all. In fact, patients treated with OP MS-1 and OP MS-1 TOP
preparations had the highest levels of IgG and IgM antibodies
TABLE 5 | Statistical analysis of results from neutralization test in 20
patients (response to MS-1 phage cocktail).
Type of phage
used in phage
therapy
Mean K rate
before therapy
±SE
Mean K rate in
patients during
therapy ±SE
Statistical
significance
(p)
S. aureus MS-1
phage cocktail
0.02 ± 0.01 23.78 ± 12.13 <0.001∗
∗Wilcoxon’s test.
TABLE 6 | Statistical analysis of results from neutralization test in 20
patients compared to 10 healthy donors (response to MS-1 phage
cocktail).
Type of phage
used in phage
therapy
Mean K rate in
healthy subjects
±SE
Mean K rate in
patients during
therapy ±SE
Statistical
significance
(p)
S. aureus MS-1
phage cocktail
0.003 ± 0.002 23.78 ± 12.13 <0.001∧
∧Mann−Whitney’s U test.
measured by the ELISA technique within the whole tested
group.
DISCUSSION
The results from earlier reports are consistent with our current
examinations and clearly show that bacteriophage can induce
production of antiphage antibodies (mostly IgG and IgM) which
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TABLE 7 | Immune response and clinical outcome of phage treatment in 20 examined patients.
Patient IgG (AU)
before
therapy
IgG (AU)
during
therapy∗
IgA (AU)
before
therapy
IgA (AU)
during
therapy∗
IgM (AU)
before
therapy
IgM (AU)
during
therapy∗
Phage
inactivation
(K) before
therapy
Phage
inactivation
(K) during
therapy∗
Clinical
outcome
of phage
therapy
1 77.82 598.84 0 0 2.07 671.4 0 204.49 F
2 108.91 124.04 0.06 0.17 0.21 6.56 0.01 0.14 F
3 58.44 65.74 0 0 0.07 0.09 0.02 0.13 E
4 26.8 662.56 0 0 10.99 136.68 0 13,94 E
5 51.72 48.87 0 0.34 0 52.82 0.03 10.84 F
6 37.82 60.92 0 0 2.15 1.12 0 0.69 E
7 171.45 345.1 0.19 34.59 197.35 1193.08 0.02 140.85 B
8 36.47 405.44 0 12.26 6.87 536.94 0 70.1 A
9 54.9 45.01 0 0 1.23 3.43 0 0.128 B
10 36 121.74 0 0 0.55 1.79 0.02 6.92 A
11 34.87 30.94 0 0 14.36 13.15 0.02 0.4 D
12 51.66 72.78 0 0 0.07 0 0 0.11 B
13 23.09 30.59 0 0 0 0 0.12 0.4 F
14 74.96 95.51 1.31 2.27 0 0.41 0.01 0.95 E
15 48.65 42.17 0 0 0 0 0.01 0.09 C, F#
16 69.92 300.28 0 1.9 0 216.57 0 10.26 D
17 95.96 136.56 0 0.16 0.61 1267.52 0.04 0.52 C
18 40.25 28.01 0 0 0.08 1.74 0.02 0.11 F
19 26.74 32.1 0 0 0 14.53 0.01 14.58 E
20 107.82 85.13 2.55 1.59 0.14 0.06 0 0.01 F
∗Maximum values achieved during treatment; #C, chronic sinusitis; F, chronic conjunctivitis.
may be responsible for phage inactivation. However, the immune
response to phages depends on many different factors (duration
of the treatment, phage dosage and route of administration).
The immune status of a patient is no less significant. Previous
reports indicated that several patients from our Phage Therapy
Unit had immune deficits caused by infections, antibiotic
treatment, etc. (Kurze˛pa-Skaradzin´ska et al., 2014). Górski et al.
(2006) assumed that phage translocation in patients may be
much higher than in healthy people as the gut barrier in
disease is often much more permeable to microorganisms.
Furthermore, in patients with immunodeficiencies, applied
phages are believed to have longer viability (Borysowski and
Górski, 2008). Some sources have noted that toxins produced
by pathogenic bacteria in humans may have an inhibitory
effect on their immune response (Gobert et al., 2007). Hentzer
et al. (2001) found that temperate P. aeruginosa phages
contribute to production of modified biofilm by pathogenic
Pseudomonas strains, which is more resistant to antimicrobial
treatments and activity of the immune system cells. As stated
before, such data are still limited, especially when relating to
human models. Pescovitz et al. (2011) noted that ϕX174 phage
circulated for 3 to 4 days after intravenous application in
healthy people until IgM antibodies completely inactivated phage
particles before day 7. IgG antibodies were induced as well.
In investigations by Bruttin and Brussow (2005), no humoral
immune response was observed after oral administration. The
authors suggested that no substantial amount of T4 phage
ever appeared in their blood. Our group obtained similar
results (Łusiak-Szelachowska et al., 2014). Although, we did not
demonstrate the presence of phages in blood, such suggestion
seems to be reasonable. Oral application induced the weakest
immunological response, but, in this study, similar low levels
of antibodies were observed in many patients after local
administration as well. In our study we were unable to assess
the direct relationship between the route of administration
and the intensity of the immune response, as the majority
of the tested group received phages locally or both locally
and orally (only in two cases were phages applied entirely
orally).
Some sources indicate that antiphage antibodies may be
present in patients’ sera before phage treatment or even in sera of
completely healthy people. Kucharewicz-Krukowska and S´lopek
(1987) observed the presence of specific antiphage antibodies
in 23% of patients before phage treatment. Our earlier work
(Łusiak-Szelachowska et al., 2014) indicated that a low level
of antiphage activity of patients’ sera could be detected before
treatment. Da˛browska et al. (2014) obtained congruous findings
when investigating the level of anti-T4 phage IgG in the human
population. Over 80% of healthy individuals were found to
have antiphage antibodies in their sera. Those antibodies, so-
called “natural antibodies” (Górski et al., 2012), may be a result
of high prevalence of phages, which are well known for their
vast abundance in almost every environment, even in the water
supply system of European cities (Weber-Da˛browska et al., 2014),
and can induce antibody production in healthy controls. Our
trials showed the presence of antiphage IgG antibodies in the
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group of 10 healthy donors at similar levels as in the group of
patients before implementation of phage therapy. We also found
correlations between the levels of antiphage IgA (undetectable
levels in the group of healthy people and exceptionally low values
in patients before and at the time of the treatment). Differences
were found in the levels of antiphage IgM. A few patients
exhibited relatively high levels of antiphage IgM antibodies before
phage application. Those levels increased rapidly at the beginning
of the treatment.
The results obtained for two patients administered purified
phage preparations provide interesting knowledge for further
development of phage therapy. Generally, the patients subjected
to treatment in the Phage Therapy Unit in Wrocław, Poland
receive phage lysates (phage particles suspended in liquid
bacterial medium) instead of purified preparations. Phage lysates
may contain macromolecules derived from the host bacteria and
culture medium. Their presence raises an important concern
regarding the safety of the therapy (Szermer-Olearnik and
Boratyn´ski, 2015). Our preliminary results suggest that those
concerns are unfounded. Based on the above observations, we
can presume that application of phage lysates does not cause
any deleterious effects compared to purified phage preparations.
However, emphasis should be laid on phage titer in both phage
preparations, which was four ranges lower in phage lysates,
making them possibly less immunogenic. It appears that phage
dose, not the level of purification of phage solution, plays the
most important role in immunogenicity of therapeutic phage
preparations in humans. However, larger cohorts of patients are
needed to draw definite conclusions.
Data from animal models are more numerous. Results
obtained by Stashak et al. (1970) and Sulakvelidze and Barrow
(2005) indicated the appearance of antiphage antibodies in
animals which are able to inactivate phages during treatment.
The latest reports have presented similar results. In a murine
model, specific immunization to T4 head proteins decreased
phage activity in vitro and in vivo in a group pre-immunized with
phage Hoc protein but only in vitro in a group pre-immunized
with gp23 protein (Da˛browska et al., 2014). Differences in
the immunogenicity of phage structural proteins were reported
by other authors. Capparelli et al. (2007) described two
staphylococcal phages, wild type and its mutant driven by the
mice immune system, which were serologically distinct. The
mutant was persistent in neutralizing antibodies in the mouse
circulation, whereas the wild phage was almost completely
inactivated within 2 days after intravenous application. A long-
term study of antibody induction in mice by T4 phage applied
orally in very high doses (4 × 109 pfu/ml thus making
approximately 2 × 1010 pfu/mouse daily; mice were fed with
T4 phage in drinking water for 100 days) showed a significant
increase in antibody levels (IgG in sera after 36 days of treatment
and IgA in feces after two months of continuous treatment).
The increased IgA level antagonized gut transit of active phage
(Majewska et al., 2015).
Finding similarities among animal and human models
encounters difficulties due to certain limitations of this study. No
doubt, animal experiments can be planned more accurately. We
were not able to assess phage viability in human tissues as was
done in animal investigations (Hodyra-Stefaniak et al., 2015) or
in the gut. The results gained so far from human stool samples
(Łusiak-Szelachowska et al., 2008) did not reflect the full scope
of events taking place within the gut during phage treatment.
Similar obstacles were faced by Sarker et al. (2016). Considering
the immunogenicity of phages in the animal gut, the term “rather
low” has been used (Majewska et al., 2015). However, one cannot
directly extrapolate those studies in mice to the clinic.
CONCLUSION
Overall, the majority of studies to date show that phages may
induce a humoral immune response in humans. Interpretations
regarding the strength of this response are often contradictory
or unclear. As described above, patients who showed the highest
level of antiphage antibodies and the highest antiphage activity
of their sera ended phage treatment with good clinical results
or even with full recovery. The significance of these findings is
not to be underestimated, as the results from animal experiments
cannot be simply transferred to a human model. Our studies
confirm and extend our earlier work indicating that phage
therapy may induce various levels of antibody formation which
does not necessarily affect the outcome of therapy. Evidently,
further studies are needed to shed more light on phage-dependent
immune responses and their significance for the success or failure
of therapy.
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